Quantitative mapping of hepatic perfusion index using MR imaging: A potential reproducible tool for assessing tumour response to treatment with the antiangiogenic compound BIBF 1120, a potent triple angiokinase inhibitor

European Radiology

Volumn 18, Issue 7, 2008, Pages 1414-1421

  Miyazaki, Keiko ^a   Collins, David J ^a   Walker Samuel, Simon ^a   Taylor, Jane N ^b   Padhani, Anwar R ^b   Leach, Martin O ^a   Koh, Dow Mu ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Dynamic liver imaging; Hepatic perfusion index; Magnetic resonance imaging

Indexed keywords

ANGIOGENESIS INHIBITOR; BIBF 1120; GADOLINIUM PENTETATE;

ADULT; AGED; ARTICLE; CHOROID MELANOMA; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTRAST ENHANCEMENT; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MONITORING; FEMALE; GASTROINTESTINAL CARCINOMA; HUMAN; IMAGE ANALYSIS; LIVER METASTASIS; LIVER PERFUSION; LUNG ADENOCARCINOMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ISLET CELL TUMOR; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; QUANTITATIVE STUDY; REPRODUCIBILITY; TREATMENT RESPONSE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INDOLES; LIVER; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; REPRODUCIBILITY OF RESULTS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 45849085389     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-008-0898-9     Document Type: Article

References (17)

1. Miles KA, Hayball MP, Dixon AK (1993) Functional images of hepatic perfusion obtained with dynamic CT. Radiology 188:405-411
2. Kissel A, Rixe O, Methlin A, Nabet M, Tranquart F, Rubini B, Jafaar S, Gaucher H (2001) Quantification of hepatic arterial and portal venous flow using ultrasound contrast agents for early detection of liver metastases of colorectal cancers. J Radiol 82:1621-1625
3. Fowler RC, Harris KM, Swift SE, Ward M, Greenwood DC (1998) Hepatic Doppler perfusion index: Measurement in nine healthy volunteers. Radiology 209:867-871
4. Blomley MJ, Coulden R, Dawson P, Kormano M, Donlan P, Bufkin C, Lipton MJ (1995) Liver perfusion studied with ultrafast CT. J Comput Assist Tomogr 19:424-433
5. Sarper R, Fajman WA, Tarcan YA, Nixon DW (1981) Enhanced detection of metastatic liver disease by computerized flow scintigrams: Concise communication. J Nucl Med 22:318-321
6. Leveson SH, Wiggins PA, Giles GR, Parkin A, Robinson PJ (1985) Deranged liver blood flow patterns in the detection of liver metastases. Br J Surg 72:128-130
7. White MJ, O'Gorman RL, Charles-Edwards EM, Kane PA, Karani JB, Leach MO, Totman JJ (2007) Parametric mapping of the hepatic perfusion index with gadolinium-enhanced volumetric MRI. Br J Radiol 80(950):113-120
8. Totman JJ, O'Gorman RL, Kane PA, Karani JB (2005) Comparison of the hepatic perfusion index measured with gadolinium-enhanced volumetric MRI in controls and in patients with colorectal cancer. Br J Radiol 78:105-109
9. Mross K, Gmehling D, Frost A, Baas FJ, Strecker R, Hennig J, Strecker P, Stefanic M, Stehle G, Rossi Ld (2005) A clinical phase I pharmacokinetic (PK) and pharmacodynamic study of twice daily BIBF 1120 in advanced cancer patients. 41st Annual Meeting of the American Society of Clinical Oncology (ASCO), Orlando
10. Hilberg F, Tontsch-Grunt U, Colbatzky F, Heckel A, Lotz R, van Meel JCA, Roth GJ (2004) BIBF 1120 - a novel, small molecule triple angiokinase inhibitor: Profiling as a clinical candidate for cancer therapy. Molecular Targets and Cancer Therapeutics, 16th EORTC-NCI-AACR Symposium, Geneva, Switzerland
11. Pedersen M, Klarhofer M, Christensen S, Ouallet JC, Ostergaard L, Dousset V, Moonen C (2004) Quantitative cerebral perfusion using the PRESTO acquisition scheme. J Magn Reson Imaging 20:930-940. DOI 10.1002/ jmri.20206
12. Hittmair K, Gomiscek G, Langenberger K, Recht M, Imhof H, Kramer J (1994) Method for the quantitative assessment of contrast agent uptake in dynamic contrast-enhanced MRI. Magn Reson Med 31:567-571
13. Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307-310
14. Padhani AR (2002) Functional MRI for anticancer therapy assessment. Eur J Cancer 38:2116-2127
15. Cuenod C, Leconte I, Siauve N, Resten A, Dromain C, Poulet B, Frouin F, Clement O, Friya G (2001) Early changes in liver perfusion caused by occult metastases in rats: Detection with quantitative CT. Radiology 218(2):556-561
16. Galbraith SM, Lodge MA, Taylor NJ, Rustin GJ, Bentzen S, Stirling JJ, Padhani AR (2002) Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: Comparison of quantitative and semi-quantitative analysis. NMR Biomed 15:132-142
17. Meijerink MR, Cruijsen H, Hoekman K, Kater M, Schaik C, Waesberghe JHTM, Giaccone G, Manoliu RA (2007) The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients. Eur Radiol 17:1700-1713. DOI 10.1007/s00330-006-0425-9